Who Paid My Doc
A Phase 1 Study of Sgnegfrd2 in Advanced Solid Tumors
Research payments
$4,167,255
Through program year 2025, $4,167,255 in research payments was reported against A Phase 1 Study of Sgnegfrd2 in Advanced Solid Tumors, across 345 payments, paid by Pfizer Inc..
- Paid by
- Pfizer Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $2,296,819 | 190 |
| 2024 | Research | $1,870,437 | 155 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Hirva Mamdani Detroit, MI Named on 153 payments
- Rachel Sanborn Portland, OR Named on 39 payments
- Martin Gutierrez Hackensack, NJ Named on 27 payments
- Richard Kim Tampa, FL Named on 23 payments
- Chandrikha Chandrasekharan Iowa City, IA Named on 10 payments
- Ravi Paluri Clemmons, NC Named on 9 payments
- Muhammad Furqan Oklahoma City, OK Named on 8 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.